Last updated on March 2017

Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma


Brief description of study

This is a Phase 2, multicenter, open-label, 2-part, single-arm, 2-stage study of tazemetostat 800 mg two times a day (BID) administered orally. Screening of subjects to determine eligibility for the study will be performed within 21 days of the first planned dose of tazemetostat. In Part 1, 12 subjects with relapsed or refractory malignant mesothelioma regardless of BAP1 status will be treated and undergo pharmacokinetics (PK) blood sample collection after a single tazemetostat 800 mg. Part 2 will include subjects with BAP1-deficient relapsed or refractory malignant mesothelioma. Treatment with tazemetostat will continue until disease progression, unacceptable toxicity or withdrawal of consent, or termination of the study. Response assessment will be evaluated after 6 weeks of treatment and then every 12 weeks thereafter while on study.

Clinical Study Identifier: NCT02860286

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Robert Cameron, MD

University of California, Los Angeles
Los Angeles, CA United States
  Connect »

Marianna Koczywas, MD

City of Hope National Medical Center
Los Angeles, CA United States
  Connect »

Thierry Jahan, MD

University of California San Francisco
San Francisco, CA United States
  Connect »

Petr Hausner, MD

University of Maryland Medical Center
Baltimore, MD United States
  Connect »

Christopher Azzoli, MD

Massachusetts General Hospital
Boston, MA United States
  Connect »

David Jackman, MD

Dana-Farber Cancer Institute
Boston, MA United States
  Connect »

Tobias Peikert, MD

Mayo Clinic - Rochester
Rochester, MN United States
  Connect »

Marjorie Zauderer, MD

Memorial Sloan Kettering Cancer Center
New York, NY United States
  Connect »

Anne Tsao, MD

MD Anderson Cancer Center
Houston, TX United States
  Connect »

Sylvestre Le Moulec, MD

Institut Bergonie
Bordeaux Cedex, France
  Connect »

Arnaud Scherpereel, MD

CHRU de Lille
Lille, France
  Connect »

David Planchard, MD

Institut Gustave Roussy
Villejuif cedex, France
  Connect »

Paul Taylor, MD

University Hospital of South Manchester
Greater Manchester, United Kingdom
  Connect »

Dean Fennel, MD

University of Leicester & Leicester University Hospitals
Leicester, United Kingdom
  Connect »

Peter Szlosarek, MD

St. Bartholomew's Hospital
London, United Kingdom
  Connect »

Martin Forster, MD

University College Hospital
London, United Kingdom
  Connect »

Sanjay Popat, MD

Royal Marsden Hospital - Chelsea
London, United Kingdom
  Connect »

Sanjay Popat, MD

Royal Marsden Hospital - Surrey
Surrey, United Kingdom
  Connect »